Literature DB >> 8717433

Role of cardiac renin-angiotensin system in the development of pressure-overload left ventricular hypertrophy in rats with abdominal aortic constriction.

D S Reddy1, M Singh, S Ghosh, N K Ganguly.   

Abstract

Possible involvement of cardiac renin-angiotensin system (RAS) in pressure overload induced left ventricular hypertrophy (LVH) was investigated. Rats were subjected to abdominal aortic constriction (AAC) and examined the effects of 4 weeks treatments with an angiotensin converting enzyme (ACE) inhibitor, captopril and a vasodilator, hydralazine on haemodynamics and ventricular RNA, DNA, protein and myosin isoform pattern in sham and hypertrophied rats. AAC increased the mean arterial pressure (MAP) and systolic blood pressure (SBP), and resulted in increased left ventricle/body weight ratio, LV thickness, RNA and protein content, however total DNA was not changed. The expression of fetal isogene, beta-myosin heavy chain (beta-MHC), was markedly enhanced where as alpha-MHC was reduced. High-dose captopril (100 mg/kg p.o.,) significantly prevented the increase in haemodynamics, development of LVH, LV remodeling, increase in total protein, RNA and antithetical expression of myosin isoforms. Hydralazine (15 mg/kg p.o.,), did not modulate hypertrophic changes and low-dose captopril (1.5 mg/kg p.o.,) which has not produced any marked fall in MAP and SBP also modulated favourably the development of LVH and its biochemical markers. Thus, the prevention of the development of LVH and induction of beta-MHC by non-hypotensive doses of captopril may be related to the blockade of intracardiac production of angiotensin II rather than circulating system. These results suggest that cardiac RAS may play an important role in pressure overload induced LVH.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8717433     DOI: 10.1007/BF00714327

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  8 in total

1.  2-Methoxyestradiol Attenuates Angiotensin II-Induced Hypertension, Cardiovascular Remodeling, and Renal Injury.

Authors:  Eman Salah; Sheldon I Bastacky; Edwin K Jackson; Stevan P Tofovic
Journal:  J Cardiovasc Pharmacol       Date:  2019-03       Impact factor: 3.105

2.  Cardiac myosin phenotype remodeling following chronic spinal transection.

Authors:  H A Kluess; A G Nelson; M A Duke
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

3.  Left ventricular hypertrophy induced by abdominal aortic banding and its prevention by angiotensin receptor blocker telmisartan--a proteomic analysis.

Authors:  Li Liu; Wen Wang; Xianmin Meng; Jiuming Gao; Haiying Wu; Peihe Wang; Weichun Wu; Linlin Wang; Liyuan Ma; Weiguo Zhang
Journal:  J Physiol Biochem       Date:  2010-08-10       Impact factor: 4.158

4.  Losartan inhibits myosin isoform shift after myocardial infarction in rats.

Authors:  Mei Luo Zhang; Samer Elkassem; Allen W Davidoff; Kaoru Saito; Henk E D J ter Keurs
Journal:  Mol Cell Biochem       Date:  2003-09       Impact factor: 3.396

5.  Inhibition of neuronal nitric oxide synthase (n-cNOS) reverses the corticotrophin-induced behavioral effects in rats.

Authors:  D S Reddy; S K Kulkarni
Journal:  Mol Cell Biochem       Date:  1998-06       Impact factor: 3.396

6.  A designed zinc-finger transcriptional repressor of phospholamban improves function of the failing heart.

Authors:  H Steve Zhang; Dingang Liu; Yan Huang; Stefan Schmidt; Reed Hickey; Dmitry Guschin; Haili Su; Ion S Jovin; Mike Kunis; Sarah Hinkley; Yuxin Liang; Linda Hinh; S Kaye Spratt; Casey C Case; Edward J Rebar; Barbara E Ehrlich; Barbara Ehrlich; Philip D Gregory; Frank J Giordano
Journal:  Mol Ther       Date:  2012-07-24       Impact factor: 11.454

7.  Early dystrophin loss is coincident with the transition of compensated cardiac hypertrophy to heart failure.

Authors:  Fernanda P Prado; Daniele O Dos Santos; Valdecir Blefari; Carlos A Silva; Juliano Machado; Isis do Carmo Kettelhut; Simone G Ramos; Marcelo Dias Baruffi; Helio C Salgado; Cibele M Prado
Journal:  PLoS One       Date:  2017-12-21       Impact factor: 3.240

8.  FKBP12.6 protects heart from AngII-induced hypertrophy through inhibiting Ca2+ /calmodulin-mediated signalling pathways in vivo and in vitro.

Authors:  Yun-Fei Xiao; Zhi-Xiong Zeng; Xiao-Hui Guan; Ling-Fang Wang; Chan-Juan Wang; Huidong Shi; Weinian Shou; Ke-Yu Deng; Hong-Bo Xin
Journal:  J Cell Mol Med       Date:  2018-04-22       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.